Covered recipient · General Payments record
EDUARDO WEISS
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$103,804.75
182 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $85,517.50 | 26 |
| Consulting Fee | $11,600.00 | 1 |
| Food and Beverage | $4,078.24 | 147 |
| Travel and Lodging | $2,509.02 | 7 |
| Education | $99.99 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Allergan, Inc. | $52,584.56 | 22 |
| ABBVIE INC. | $45,586.20 | 73 |
| Galderma Laboratories, L.P. | $3,614.75 | 5 |
| Janssen Biotech, Inc. | $406.43 | 16 |
| Sun Pharmaceutical Industries Inc. | $322.89 | 4 |
| PFIZER INC. | $211.00 | 16 |
| Regeneron Healthcare Solutions, Inc. | $168.00 | 9 |
| E.R. Squibb & Sons, L.L.C. | $161.63 | 3 |
| GENZYME CORPORATION | $139.56 | 6 |
| EPI Health, LLC | $138.02 | 7 |
| LEO Pharma Inc. | $131.23 | 6 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $75.91 | 3 |
| Novartis Pharmaceuticals Corporation | $75.68 | 4 |
| Lilly USA, LLC | $72.38 | 3 |
| UCB, Inc. | $67.95 | 2 |
| iCAD, Inc | $25.40 | 2 |
| Amgen Inc. | $23.16 | 1 |
Page 4 of 4; records 151–182 of 182 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
EDUARDO WEISS
NPI 1053308965 · CMS profile ID 2793
Allopathic & Osteopathic Physicians / Dermatology
HOLLYWOOD, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–182 of 182 matching records. This page contains 32 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1053308965?year=2022&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- EDUARDO WEISS, NPI 1053308965, CMS profile ID 2793. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–182 of 182 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053308965?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). EDUARDO WEISS, NPI 1053308965, CMS profile ID 2793. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–182 of 182 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053308965?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- EDUARDO WEISS, NPI 1053308965, CMS profile ID 2793, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–182 of 182 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1053308965?year=2022&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
182 matching records · $103,804.75 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–182 of 182.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.09 | 03/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892627959 | CMS |
| Janssen Biotech, Inc. | $27.21 | 03/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885672207 | CMS |
| Sun Pharmaceutical Industries Inc. | $139.95 | 02/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947765293 | CMS |
| Regeneron Healthcare Solutions, Inc. | $5.59 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927469543 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1.83 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927469549 | CMS |
| Lilly USA, LLC | $25.62 | 02/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918066093 | CMS |
| ABBVIE INC. | $4.77 | 02/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892627953 | CMS |
| ABBVIE INC. | $3,125.00 | 02/21/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892627955 | CMS |
| ABBVIE INC. | $26.00 | 02/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892627957 | CMS |
| PFIZER INC. | $20.73 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949118231 | CMS |
| ABBVIE INC. | $123.53 | 02/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892627951 | CMS |
| Janssen Biotech, Inc. | $31.20 | 02/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885672225 | CMS |
| Janssen Biotech, Inc. | $19.74 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885672149 | CMS |
| Allergan, Inc. | $4,550.00 | 02/07/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890005563 | CMS |
| Regeneron Healthcare Solutions, Inc. | $15.52 | 02/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927469537 | CMS |
| ABBVIE INC. | $5.02 | 02/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892627949 | CMS |
| Novartis Pharmaceuticals Corporation | $19.49 | 02/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894446547 | CMS |
| Allergan, Inc. | $4,550.00 | 01/31/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890005561 | CMS |
| Janssen Biotech, Inc. | $18.28 | 01/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885672189 | CMS |
| EPI Health, LLC | $2.98 | 01/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 960437433 | CMS |
| LEO Pharma Inc. | $19.58 | 01/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 936302673 | CMS |
| Allergan, Inc. | $4,550.00 | 01/24/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890005559 | CMS |
| Lilly USA, LLC | $25.98 | 01/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918008837 | CMS |
| Allergan, Inc. | $1,950.00 | 01/19/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890005557 | CMS |
| ABBVIE INC. | $21.68 | 01/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892627947 | CMS |
| Allergan, Inc. | $4,550.00 | 01/17/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890005555 | CMS |
| EPI Health, LLC | $23.76 | 01/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 960437431 | CMS |
| ABBVIE INC. | $21.00 | 01/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 892627945 | CMS |
| Allergan, Inc. | $4,550.00 | 01/11/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890005553 | CMS |
| GENZYME CORPORATION | $21.32 | 01/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938856853 | CMS |
| Allergan, Inc. | $4,550.00 | 01/07/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890005549 | CMS |
| Allergan, Inc. | $23.49 | 01/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890005551 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,099,342.79 | 594 |
| PY2024 | Recipient | $104.58 | 1 |
| PY2024 | Principal investigator | $1,073,446.45 | 743 |
| PY2023 | Principal investigator | $729,924.19 | 415 |
| PY2022 | Recipient | $944.00 | 1 |
| PY2022 | Principal investigator | $595,300.50 | 78 |
| PY2021 | Recipient | $839.52 | 1 |
| PY2021 | Principal investigator | $868,543.94 | 73 |
| PY2020 | Recipient | $293.47 | 1 |
| PY2020 | Principal investigator | $383,597.48 | 59 |
| PY2019 | Recipient | $5,000.00 | 1 |
| PY2019 | Principal investigator | $324,257.25 | 38 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
594 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,529.40 | 12/31/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH LLC | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata | No dispute reported | 06/30/2026 | 1202533091 |
| Principal investigator 1 | ABBVIE INC. | $665.04 | 12/31/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH LLC | A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202533271 |
| Principal investigator 1 | ABBVIE INC. | $3,537.36 | 12/31/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH LLC | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | No dispute reported | 06/30/2026 | 1202533273 |
| Principal investigator 1 | PFIZER INC. | $1,050.72 | 12/31/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228804244 |
| Principal investigator 1 | ABBVIE INC. | $355.11 | 12/30/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202532174 |
| Principal investigator 1 | ABBVIE INC. | $268.99 | 12/30/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202532176 |
| Principal investigator 1 | ABBVIE INC. | $222.63 | 12/30/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202532188 |
| Principal investigator 1 | Incyte Corporation | $264.00 | 12/19/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590097 |
| Principal investigator 1 | Incyte Corporation | $1,784.00 | 12/19/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590132 |
| Principal investigator 1 | Incyte Corporation | $270.00 | 12/19/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590175 |
| Principal investigator 1 | Incyte Corporation | $225.00 | 12/19/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590185 |
| Principal investigator 1 | ABBVIE INC. | $784.00 | 12/16/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202530586 |
| Principal investigator 1 | ABBVIE INC. | $824.00 | 12/16/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202530594 |
| Principal investigator 1 | ABBVIE INC. | $704.00 | 12/11/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202530086 |
| Principal investigator 1 | ABBVIE INC. | $60.00 | 12/11/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202530088 |
| Principal investigator 1 | Incyte Corporation | $76.00 | 12/11/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240590067 |
| Principal investigator 1 | Incyte Corporation | $9,930.60 | 12/11/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240590075 |
| Principal investigator 1 | Incyte Corporation | $229.00 | 12/11/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240590080 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $800.00 | 12/09/2025 | Non-covered Recipient Entity Skin Care Research, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246434467 |
| Principal investigator 1 | Incyte Corporation | $5,147.20 | 12/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590214 |
| Principal investigator 1 | ABBVIE INC. | $41,069.93 | 12/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202527346 |
| Principal investigator 1 | ABBVIE INC. | $6,432.60 | 12/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202527348 |
| Principal investigator 1 | ABBVIE INC. | $6,583.05 | 12/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202527440 |
| Principal investigator 1 | ABBVIE INC. | $4,693.00 | 12/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202527682 |
| Principal investigator 1 | Incyte Corporation | $420.70 | 12/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240590085 |
| Principal investigator 1 | Incyte Corporation | $5,359.80 | 12/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240590071 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202526182 |
| Principal investigator 1 | Incyte Corporation | $1,944.00 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590089 |
| Principal investigator 1 | Incyte Corporation | $3.18 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590093 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590110 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590113 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590117 |
| Principal investigator 1 | Incyte Corporation | $43.56 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590121 |
| Principal investigator 1 | Incyte Corporation | $1.70 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590128 |
| Principal investigator 1 | Incyte Corporation | $131.56 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590136 |
| Principal investigator 1 | Incyte Corporation | $7.11 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590140 |
| Principal investigator 1 | Incyte Corporation | $7.11 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590144 |
| Principal investigator 1 | Incyte Corporation | $2.37 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590152 |
| Principal investigator 1 | Incyte Corporation | $2.37 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590156 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590160 |
| Principal investigator 1 | Incyte Corporation | $123.40 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590163 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590167 |
| Principal investigator 1 | Incyte Corporation | $88.00 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590178 |
| Principal investigator 1 | Incyte Corporation | $23.70 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590189 |
| Principal investigator 1 | Incyte Corporation | $870.00 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590193 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590198 |
| Principal investigator 1 | Incyte Corporation | $21.33 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590207 |
| Principal investigator 1 | Incyte Corporation | $9.48 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590222 |
| Principal investigator 1 | Incyte Corporation | $118.50 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590226 |
| Principal investigator 1 | Incyte Corporation | $118.50 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590230 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590232 |
| Principal investigator 1 | Incyte Corporation | $1,977.00 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590235 |
| Principal investigator 1 | Incyte Corporation | $14.22 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590240 |
| Principal investigator 1 | Incyte Corporation | $47.40 | 12/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590244 |
| Principal investigator 1 | ABBVIE INC. | $1,430.63 | 11/26/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202525680 |
| Principal investigator 1 | Incyte Corporation | $65.00 | 11/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240590042 |
| Principal investigator 1 | Incyte Corporation | $134.00 | 11/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240590063 |
| Principal investigator 1 | Incyte Corporation | $1,249.20 | 11/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590218 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $22,300.00 | 11/24/2025 | Non-covered Recipient Entity Skin Care Research, LLC | Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata | No dispute reported | 06/30/2026 | 1252797092 |
| Principal investigator 1 | ABBVIE INC. | $259.44 | 11/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202524776 |
| Principal investigator 1 | ABBVIE INC. | $5,158.00 | 11/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202525008 |
| Principal investigator 1 | ABBVIE INC. | $1,006.87 | 11/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202525018 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 11/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240590034 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 11/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240590059 |
| Principal investigator 1 | ABBVIE INC. | $207.90 | 11/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202524467 |
| Principal investigator 1 | ABBVIE INC. | $300.00 | 11/13/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202524031 |
| Principal investigator 1 | Incyte Corporation | $104.00 | 11/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240590038 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 11/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240590046 |
| Principal investigator 1 | Incyte Corporation | $126.00 | 11/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240590050 |
| Principal investigator 1 | Incyte Corporation | $835.00 | 11/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240590053 |
| Principal investigator 1 | Incyte Corporation | $2,665.00 | 11/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240590056 |
| Principal investigator 1 | ABBVIE INC. | $17,852.35 | 11/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202522891 |
| Principal investigator 1 | ABBVIE INC. | $2,119.30 | 11/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202522951 |
| Principal investigator 1 | ABBVIE INC. | $4,849.25 | 11/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202522953 |
| Principal investigator 1 | ABBVIE INC. | $4,136.40 | 11/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202521143 |
| Principal investigator 1 | ABBVIE INC. | $4,174.27 | 11/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202521145 |
| Principal investigator 1 | PFIZER INC. | $365.85 | 11/04/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228817328 |
| Principal investigator 1 | Incyte Corporation | $124.54 | 11/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590105 |
| Principal investigator 1 | Incyte Corporation | $137.40 | 11/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590125 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 11/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590171 |
| Principal investigator 1 | Incyte Corporation | $1,842.30 | 10/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240590020 |
| Principal investigator 1 | ABBVIE INC. | $2,491.00 | 10/28/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH LLC | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202518737 |
| Principal investigator 1 | ABBVIE INC. | $87.12 | 10/28/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202518739 |
| Principal investigator 1 | ABBVIE INC. | $227.70 | 10/23/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202518259 |
| Principal investigator 1 | Incyte Corporation | $2,714.40 | 10/23/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240590031 |
| Principal investigator 1 | ABBVIE INC. | $261.56 | 10/21/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202517481 |
| Principal investigator 1 | ABBVIE INC. | $261.56 | 10/21/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202517497 |
| Principal investigator 1 | PFIZER INC. | $2,891.63 | 10/21/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228823725 |
| Principal investigator 1 | PFIZER INC. | $1,050.72 | 10/21/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228824255 |
| Principal investigator 1 | Incyte Corporation | $1,920.60 | 10/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590203 |
| Principal investigator 1 | ABBVIE INC. | $3,940.00 | 10/16/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202517145 |
| Principal investigator 1 | Eli Lilly and Company | $2,556.00 | 10/14/2025 | Non-covered Recipient Entity INTERNATIONAL DERMATOLOGY RESEARCH | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187883868 |
| Principal investigator 1 | Incyte Corporation | $132.00 | 10/13/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590100 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,479.95 | 10/10/2025 | Non-covered Recipient Entity Skin Care Research, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246434463 |
| Principal investigator 1 | ABBVIE INC. | $5,313.60 | 10/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202513967 |
| Principal investigator 1 | ABBVIE INC. | $6,755.04 | 10/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202513969 |
| Principal investigator 1 | ABBVIE INC. | $5,834.57 | 10/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202514129 |
| Principal investigator 1 | ABBVIE INC. | $370.93 | 10/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202514131 |
| Principal investigator 1 | ABBVIE INC. | $11,151.00 | 10/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202514291 |
| Principal investigator 1 | ABBVIE INC. | $17,176.69 | 10/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202514293 |
| Principal investigator 1 | ABBVIE INC. | $7,929.72 | 10/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202514457 |
| Principal investigator 1 | Incyte Corporation | $521.00 | 10/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240590016 |
| Principal investigator 1 | Incyte Corporation | $104.00 | 10/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240590024 |
| Principal investigator 1 | Incyte Corporation | $265.00 | 10/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240590027 |
| Principal investigator 1 | Incyte Corporation | $2,013.30 | 10/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590182 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $526.62 | 10/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190311105 |
| Principal investigator 1 | ABBVIE INC. | $2,472.00 | 10/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202513059 |
| Principal investigator 1 | Incyte Corporation | $1,035.80 | 10/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590148 |
| Principal investigator 1 | Incyte Corporation | $2,134.00 | 10/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590211 |
| Principal investigator 1 | Janssen Research & Development, LLC | $406.00 | 10/02/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187076 |
| Principal investigator 1 | ABBVIE INC. | $2,352.00 | 09/26/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202512502 |
| Principal investigator 1 | ABBVIE INC. | $8,183.00 | 09/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202512092 |
| Principal investigator 1 | Incyte Corporation | $1,853.10 | 09/18/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589874 |
| Principal investigator 1 | ABBVIE INC. | $3.64 | 09/16/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202511030 |
| Principal investigator 1 | Incyte Corporation | $290.00 | 09/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589949 |
| Principal investigator 1 | Incyte Corporation | $98.74 | 09/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589986 |
| Principal investigator 1 | ABBVIE INC. | $3,912.92 | 09/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202509312 |
| Principal investigator 1 | ABBVIE INC. | $11,913.37 | 09/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202509314 |
| Principal investigator 1 | ABBVIE INC. | $44,042.40 | 09/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202509572 |
| Principal investigator 1 | ABBVIE INC. | $13,813.00 | 09/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202507659 |
| Principal investigator 1 | ABBVIE INC. | $1,805.70 | 09/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202507885 |
| Principal investigator 1 | Incyte Corporation | $21.88 | 09/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589938 |
| Principal investigator 1 | Incyte Corporation | $25.95 | 09/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589945 |
| Principal investigator 1 | ABBVIE INC. | $723.12 | 09/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202506945 |
| Principal investigator 1 | PFIZER INC. | $97.00 | 08/30/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228842480 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 08/26/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202505807 |
| Principal investigator 1 | ABBVIE INC. | $492.36 | 08/26/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202505847 |
| Principal investigator 1 | Incyte Corporation | $467.00 | 08/22/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589886 |
| Principal investigator 1 | Incyte Corporation | $88.00 | 08/22/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589896 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 08/22/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589900 |
| Principal investigator 1 | Incyte Corporation | $65.00 | 08/21/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589857 |
| Principal investigator 1 | Incyte Corporation | $1,760.90 | 08/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589883 |
| Principal investigator 1 | Incyte Corporation | $1,388.00 | 08/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589917 |
| Principal investigator 1 | Incyte Corporation | $1,388.00 | 08/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590013 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $405.00 | 08/20/2025 | Non-covered Recipient Entity Skin Care Research, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246434459 |
| Principal investigator 1 | ABBVIE INC. | $1,144.02 | 08/14/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202504797 |
| Principal investigator 1 | Incyte Corporation | $602.80 | 08/14/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589868 |
| Principal investigator 1 | Incyte Corporation | $2,191.50 | 08/14/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589871 |
| Principal investigator 1 | ABBVIE INC. | $191.10 | 08/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202504123 |
| Principal investigator 1 | Incyte Corporation | $70.83 | 08/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589904 |
| Principal investigator 1 | Incyte Corporation | $66.00 | 08/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589961 |
| Principal investigator 1 | Incyte Corporation | $58.00 | 08/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589965 |
| Principal investigator 1 | Incyte Corporation | $707.52 | 08/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589970 |
| Principal investigator 1 | Incyte Corporation | $126.00 | 08/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589973 |
| Principal investigator 1 | Incyte Corporation | $158.00 | 08/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590003 |
| Principal investigator 1 | ABBVIE INC. | $74.18 | 08/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202503877 |
| Principal investigator 1 | ABBVIE INC. | $27.82 | 08/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202503917 |
| Principal investigator 1 | ABBVIE INC. | $18.55 | 08/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202503943 |
| Principal investigator 1 | Eli Lilly and Company | $100.00 | 08/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH LLC | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187889998 |
| Principal investigator 1 | Incyte Corporation | $470.70 | 08/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589861 |
| Principal investigator 1 | Incyte Corporation | $650.00 | 08/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589865 |
| Principal investigator 1 | ABBVIE INC. | $471.15 | 08/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202502983 |
| Principal investigator 1 | ABBVIE INC. | $12,489.48 | 08/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202502985 |
| Principal investigator 1 | ABBVIE INC. | $317.52 | 08/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202503115 |
| Principal investigator 1 | ABBVIE INC. | $52,304.39 | 08/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202503117 |
| Principal investigator 1 | ABBVIE INC. | $1,415.55 | 08/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202503213 |
| Principal investigator 1 | ABBVIE INC. | $1,674.84 | 08/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202501582 |
| Principal investigator 1 | ABBVIE INC. | $130.38 | 08/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202501714 |
| Principal investigator 1 | ABBVIE INC. | $66.65 | 08/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202501716 |
| Principal investigator 1 | ABBVIE INC. | $2,538.00 | 08/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202501794 |
| Principal investigator 1 | ABBVIE INC. | $396.67 | 08/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202501886 |
| Principal investigator 1 | ABBVIE INC. | $62.82 | 08/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202501888 |
| Principal investigator 1 | PFIZER INC. | $136.00 | 08/05/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228842474 |
| Principal investigator 1 | Incyte Corporation | $1,419.30 | 08/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589941 |
| Principal investigator 1 | ABBVIE INC. | $296.31 | 07/31/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202500616 |
| Principal investigator 1 | ABBVIE INC. | $139.67 | 07/30/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202500528 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 07/30/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187321 |
| Principal investigator 1 | ABBVIE INC. | $3,126.18 | 07/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202500310 |
| Principal investigator 1 | ABBVIE INC. | $229.50 | 07/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202500312 |
| Principal investigator 1 | ABBVIE INC. | $1,959.60 | 07/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202500394 |
| Principal investigator 1 | Incyte Corporation | $600.00 | 07/28/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589878 |
| Principal investigator 1 | Janssen Research & Development, LLC | $419.00 | 07/28/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187146 |
| Principal investigator 1 | PFIZER INC. | $1,050.72 | 07/25/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228844928 |
| Principal investigator 1 | ABBVIE INC. | $6,491.00 | 07/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202499532 |
| Principal investigator 1 | ABBVIE INC. | $1,089.00 | 07/23/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202499312 |
| Principal investigator 1 | Incyte Corporation | $168.61 | 07/23/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589891 |
| Principal investigator 1 | Incyte Corporation | $378.00 | 07/23/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589908 |
| Principal investigator 1 | Incyte Corporation | $1,944.00 | 07/22/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240589827 |
| Principal investigator 1 | Incyte Corporation | $5,877.00 | 07/22/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589842 |
| Principal investigator 1 | Incyte Corporation | $1,694.10 | 07/18/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589953 |
| Principal investigator 1 | Incyte Corporation | $2,265.00 | 07/18/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589957 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,090.80 | 07/18/2025 | Non-covered Recipient Entity Skin Care Research, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246434455 |
| Principal investigator 1 | Incyte Corporation | $1,731.60 | 07/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589834 |
| Principal investigator 1 | Incyte Corporation | $464.00 | 07/14/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589982 |
| Principal investigator 1 | Incyte Corporation | $189.00 | 07/10/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589831 |
| Principal investigator 1 | Incyte Corporation | $1,482.50 | 07/10/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589839 |
| Principal investigator 1 | Incyte Corporation | $83.40 | 07/10/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589846 |
| Principal investigator 1 | Incyte Corporation | $417.00 | 07/10/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589849 |
| Principal investigator 1 | Incyte Corporation | $590.75 | 07/10/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589854 |
| Principal investigator 1 | Incyte Corporation | $1,631.90 | 07/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589914 |
| Principal investigator 1 | Incyte Corporation | $1,271.56 | 07/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589919 |
| Principal investigator 1 | Incyte Corporation | $294.00 | 07/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589924 |
| Principal investigator 1 | Incyte Corporation | $2,237.00 | 07/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589928 |
| Principal investigator 1 | Incyte Corporation | $132.00 | 07/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589932 |
| Principal investigator 1 | Incyte Corporation | $58.00 | 07/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589935 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 07/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589997 |
| Principal investigator 1 | Incyte Corporation | $109.56 | 07/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590006 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 07/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240590009 |
| Principal investigator 1 | ABBVIE INC. | $70.00 | 07/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202497394 |
| Principal investigator 1 | Janssen Research & Development, LLC | $100.00 | 07/04/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187085 |
| Principal investigator 1 | ABBVIE INC. | $2,633.40 | 07/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202494463 |
| Principal investigator 1 | ABBVIE INC. | $2,106.00 | 07/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202494591 |
| Principal investigator 1 | ABBVIE INC. | $3,015.72 | 07/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202494689 |
| Principal investigator 1 | ABBVIE INC. | $28,527.93 | 07/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202494691 |
| Principal investigator 1 | ABBVIE INC. | $1,716.15 | 07/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202494825 |
| Principal investigator 1 | ABBVIE INC. | $4,910.10 | 07/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202496269 |
| Principal investigator 1 | ABBVIE INC. | $824.00 | 07/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202493773 |
| Principal investigator 1 | ABBVIE INC. | $784.00 | 07/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202493775 |
| Principal investigator 1 | ABBVIE INC. | $350.00 | 07/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202493835 |
| Principal investigator 1 | Incyte Corporation | $3.18 | 07/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589977 |
| Principal investigator 1 | Incyte Corporation | $148.85 | 07/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589990 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 07/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589994 |
| Principal investigator 1 | ABBVIE INC. | $704.00 | 06/26/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202493207 |
| Principal investigator 1 | PFIZER INC. | $2,441.73 | 06/26/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228852358 |
| Principal investigator 1 | Incyte Corporation | $597.40 | 06/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589514 |
| Principal investigator 1 | Incyte Corporation | $2,134.00 | 06/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589517 |
| Principal investigator 1 | Incyte Corporation | $1,498.00 | 06/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589733 |
| Principal investigator 1 | Incyte Corporation | $1,498.00 | 06/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589738 |
| Principal investigator 1 | Incyte Corporation | $1,388.00 | 06/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589791 |
| Principal investigator 1 | Janssen Research & Development, LLC | $419.00 | 06/24/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187258 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,428.00 | 06/24/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187348 |
| Principal investigator 1 | ABBVIE INC. | $548.10 | 06/18/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202492145 |
| Principal investigator 1 | ABBVIE INC. | $59.76 | 06/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202491725 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $51,564.90 | 06/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190311107 |
| Principal investigator 1 | ABBVIE INC. | $60.00 | 06/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202491103 |
| Principal investigator 1 | Incyte Corporation | $1,844.10 | 06/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589373 |
| Principal investigator 1 | ABBVIE INC. | $67.32 | 06/10/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202490699 |
| Principal investigator 1 | Incyte Corporation | $1,419.30 | 06/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589531 |
| Principal investigator 1 | ABBVIE INC. | $1,230.00 | 06/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202490351 |
| Principal investigator 1 | ABBVIE INC. | $996.00 | 06/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202490391 |
| Principal investigator 1 | Incyte Corporation | $88.00 | 06/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589527 |
| Principal investigator 1 | Incyte Corporation | $736.32 | 06/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589535 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 06/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589540 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 06/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589793 |
| Principal investigator 1 | ABBVIE INC. | $6,580.55 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202487727 |
| Principal investigator 1 | ABBVIE INC. | $5,869.38 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202487729 |
| Principal investigator 1 | ABBVIE INC. | $125.00 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202487791 |
| Principal investigator 1 | ABBVIE INC. | $4,564.00 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202487793 |
| Principal investigator 1 | ABBVIE INC. | $2,556.60 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202487987 |
| Principal investigator 1 | ABBVIE INC. | $1,978.50 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202487989 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589644 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589648 |
| Principal investigator 1 | Incyte Corporation | $0.93 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589652 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589655 |
| Principal investigator 1 | Incyte Corporation | $41.20 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589671 |
| Principal investigator 1 | Incyte Corporation | $16.48 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589683 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589686 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589699 |
| Principal investigator 1 | Incyte Corporation | $21.87 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589703 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589802 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 06/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589807 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $800.00 | 06/03/2025 | Non-covered Recipient Entity Skin Care Research, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246434451 |
| Principal investigator 1 | ABBVIE INC. | $127.32 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202486793 |
| Principal investigator 1 | ABBVIE INC. | $379.50 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202486795 |
| Principal investigator 1 | ABBVIE INC. | $72.33 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202486801 |
| Principal investigator 1 | ABBVIE INC. | $156.83 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202486803 |
| Principal investigator 1 | ABBVIE INC. | $556.14 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202486827 |
| Principal investigator 1 | ABBVIE INC. | $9,291.00 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202486937 |
| Principal investigator 1 | ABBVIE INC. | $784.00 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202486999 |
| Principal investigator 1 | ABBVIE INC. | $273.24 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202487001 |
| Principal investigator 1 | ABBVIE INC. | $506.90 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202487003 |
| Principal investigator 1 | ABBVIE INC. | $704.00 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202487007 |
| Principal investigator 1 | ABBVIE INC. | $224.40 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202487081 |
| Principal investigator 1 | ABBVIE INC. | $43.56 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202487083 |
| Principal investigator 1 | ABBVIE INC. | $120.00 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202487085 |
| Principal investigator 1 | ABBVIE INC. | $824.00 | 05/29/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202487095 |
| Principal investigator 1 | Incyte Corporation | $11,754.00 | 05/28/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589369 |
| Principal investigator 1 | ABBVIE INC. | $60.00 | 05/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202486153 |
| Principal investigator 1 | ABBVIE INC. | $215.16 | 05/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202486159 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 05/27/2025 | Non-covered Recipient Entity Skin Care Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226145062 |
| Principal investigator 1 | ABBVIE INC. | $83.46 | 05/22/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202485755 |
| Principal investigator 1 | Incyte Corporation | $470.70 | 05/22/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589348 |
| Principal investigator 1 | Incyte Corporation | $1,388.00 | 05/21/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589442 |
| Principal investigator 1 | Incyte Corporation | $1,388.00 | 05/21/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589446 |
| Principal investigator 1 | Incyte Corporation | $1,070.60 | 05/21/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589452 |
| Principal investigator 1 | Eli Lilly and Company | $1,200.00 | 05/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH LLC | AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR | No dispute reported | 06/30/2026 | 1187889996 |
| Principal investigator 1 | Incyte Corporation | $1,106.61 | 05/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589344 |
| Principal investigator 1 | Incyte Corporation | $209.00 | 05/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589353 |
| Principal investigator 1 | Incyte Corporation | $76.00 | 05/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589357 |
| Principal investigator 1 | Incyte Corporation | $144.00 | 05/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589361 |
| Principal investigator 1 | Incyte Corporation | $3,267.00 | 05/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589365 |
| Principal investigator 1 | ABBVIE INC. | $440.00 | 05/13/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202484683 |
| Principal investigator 1 | ABBVIE INC. | $1,078.44 | 05/13/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202484689 |
| Principal investigator 1 | Incyte Corporation | $90.00 | 05/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589457 |
| Principal investigator 1 | Incyte Corporation | $132.00 | 05/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589461 |
| Principal investigator 1 | Incyte Corporation | $88.00 | 05/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589468 |
| Principal investigator 1 | Incyte Corporation | $787.08 | 05/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589472 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 05/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589476 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 05/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589712 |
| Principal investigator 1 | ABBVIE INC. | $784.00 | 05/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202484499 |
| Principal investigator 1 | ABBVIE INC. | $43.56 | 05/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202484503 |
| Principal investigator 1 | ABBVIE INC. | $118.80 | 05/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202484529 |
| Principal investigator 1 | ABBVIE INC. | $32,923.78 | 05/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202482433 |
| Principal investigator 1 | ABBVIE INC. | $4,567.47 | 05/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202482571 |
| Principal investigator 1 | ABBVIE INC. | $3,310.08 | 05/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202483559 |
| Principal investigator 1 | ABBVIE INC. | $10,726.22 | 05/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202484021 |
| Principal investigator 1 | Incyte Corporation | $1,608.00 | 05/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589486 |
| Principal investigator 1 | Incyte Corporation | $1,419.30 | 05/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589490 |
| Principal investigator 1 | ABBVIE INC. | $27.82 | 05/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202481173 |
| Principal investigator 1 | ABBVIE INC. | $111.28 | 05/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202481207 |
| Principal investigator 1 | ABBVIE INC. | $3,466.00 | 05/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202481289 |
| Principal investigator 1 | ABBVIE INC. | $125.19 | 05/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202481957 |
| Principal investigator 1 | ABBVIE INC. | $55.64 | 05/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202482239 |
| Principal investigator 1 | ABBVIE INC. | $139.10 | 05/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202482265 |
| Principal investigator 1 | ABBVIE INC. | $1,576.40 | 05/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202482267 |
| Principal investigator 1 | PFIZER INC. | $1,050.72 | 05/06/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228856166 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,265.00 | 05/05/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187354 |
| Principal investigator 1 | Incyte Corporation | $348.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589381 |
| Principal investigator 1 | Incyte Corporation | $75.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589393 |
| Principal investigator 1 | Incyte Corporation | $34.01 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589397 |
| Principal investigator 1 | Incyte Corporation | $86.94 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589402 |
| Principal investigator 1 | Incyte Corporation | $88.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589428 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589464 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589479 |
| Principal investigator 1 | Incyte Corporation | $372.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589482 |
| Principal investigator 1 | Incyte Corporation | $66.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589495 |
| Principal investigator 1 | Incyte Corporation | $413.16 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589499 |
| Principal investigator 1 | Incyte Corporation | $168.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589503 |
| Principal investigator 1 | Incyte Corporation | $1,022.40 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589507 |
| Principal investigator 1 | Incyte Corporation | $66.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589511 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589523 |
| Principal investigator 1 | Incyte Corporation | $58.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589556 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589660 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589663 |
| Principal investigator 1 | Incyte Corporation | $12.72 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589668 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589675 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589678 |
| Principal investigator 1 | Incyte Corporation | $98.72 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589692 |
| Principal investigator 1 | Incyte Corporation | $160.30 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589695 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589710 |
| Principal investigator 1 | Incyte Corporation | $1,388.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589717 |
| Principal investigator 1 | Incyte Corporation | $210.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589730 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589746 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589753 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589758 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589763 |
| Principal investigator 1 | Incyte Corporation | $116.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589788 |
| Principal investigator 1 | Incyte Corporation | $1,498.00 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589797 |
| Principal investigator 1 | Incyte Corporation | $50.90 | 05/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589823 |
| Principal investigator 1 | ABBVIE INC. | $153.01 | 05/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202480771 |
| Principal investigator 1 | ABBVIE INC. | $55.64 | 05/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202480863 |
| Principal investigator 1 | ABBVIE INC. | $282.48 | 04/30/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202480501 |
| Principal investigator 1 | ABBVIE INC. | $824.00 | 04/30/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202480633 |
| Principal investigator 1 | ABBVIE INC. | $1,345.50 | 04/30/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202480635 |
| Principal investigator 1 | ABBVIE INC. | $178.20 | 04/28/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202479748 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,500.00 | 04/28/2025 | Non-covered Recipient Entity Skin Care Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145052 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,349.00 | 04/28/2025 | Non-covered Recipient Entity Skin Care Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226145055 |
| Principal investigator 1 | ABBVIE INC. | $55.95 | 04/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202478796 |
| Principal investigator 1 | ABBVIE INC. | $158.20 | 04/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202478800 |
| Principal investigator 1 | ABBVIE INC. | $704.00 | 04/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202478812 |
| Principal investigator 1 | ABBVIE INC. | $120.00 | 04/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202478816 |
| Principal investigator 1 | ABBVIE INC. | $58.91 | 04/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202478860 |
| Principal investigator 1 | Incyte Corporation | $2,735.10 | 04/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) | No dispute reported | 06/30/2026 | 1240589377 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,021.00 | 04/24/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187051 |
| Principal investigator 1 | Janssen Research & Development, LLC | $134.00 | 04/24/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187130 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,457.00 | 04/24/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187138 |
| Principal investigator 1 | Incyte Corporation | $130.00 | 04/23/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589321 |
| Principal investigator 1 | ABBVIE INC. | $241.80 | 04/22/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH LLC | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202478257 |
| Principal investigator 1 | Incyte Corporation | $497.00 | 04/18/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589390 |
| Principal investigator 1 | Incyte Corporation | $42.00 | 04/18/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589412 |
| Principal investigator 1 | Incyte Corporation | $1,929.76 | 04/18/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589419 |
| Principal investigator 1 | Incyte Corporation | $120.00 | 04/18/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589424 |
| Principal investigator 1 | ABBVIE INC. | $704.00 | 04/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202477288 |
| Principal investigator 1 | ABBVIE INC. | $784.00 | 04/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202477313 |
| Principal investigator 1 | ABBVIE INC. | $824.00 | 04/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202477721 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,181.60 | 04/17/2025 | Non-covered Recipient Entity Skin Care Research, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246434447 |
| Principal investigator 1 | ABBVIE INC. | $1,341.80 | 04/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202476438 |
| Principal investigator 1 | ABBVIE INC. | $432.40 | 04/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202476442 |
| Principal investigator 1 | ABBVIE INC. | $110.98 | 04/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202476460 |
| Principal investigator 1 | Incyte Corporation | $257.15 | 04/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589313 |
| Principal investigator 1 | Incyte Corporation | $484.25 | 04/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589317 |
| Principal investigator 1 | Incyte Corporation | $417.00 | 04/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589325 |
| Principal investigator 1 | Incyte Corporation | $1,853.10 | 04/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589329 |
| Principal investigator 1 | Incyte Corporation | $104.25 | 04/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589333 |
| Principal investigator 1 | Incyte Corporation | $312.75 | 04/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589337 |
| Principal investigator 1 | ABBVIE INC. | $55.64 | 04/09/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202475080 |
| Principal investigator 1 | ABBVIE INC. | $6,648.00 | 04/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202474871 |
| Principal investigator 1 | Incyte Corporation | $406.00 | 04/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589407 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 04/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589415 |
| Principal investigator 1 | Incyte Corporation | $2,237.00 | 04/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589431 |
| Principal investigator 1 | Incyte Corporation | $2,237.00 | 04/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589434 |
| Principal investigator 1 | Incyte Corporation | $232.00 | 04/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589439 |
| Principal investigator 1 | Incyte Corporation | $432.80 | 04/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589777 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 04/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589783 |
| Principal investigator 1 | Incyte Corporation | $2,237.00 | 04/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589819 |
| Principal investigator 1 | ABBVIE INC. | $1,408.00 | 04/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202468793 |
| Principal investigator 1 | ABBVIE INC. | $553.40 | 04/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202469425 |
| Principal investigator 1 | ABBVIE INC. | $1,230.60 | 04/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202469607 |
| Principal investigator 1 | ABBVIE INC. | $6,351.00 | 04/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202469609 |
| Principal investigator 1 | ABBVIE INC. | $24,826.54 | 04/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202470448 |
| Principal investigator 1 | ABBVIE INC. | $6,846.12 | 04/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202473751 |
| Principal investigator 1 | ABBVIE INC. | $1,936.46 | 04/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202473942 |
| Principal investigator 1 | ABBVIE INC. | $5,092.65 | 04/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202473946 |
| Principal investigator 1 | Incyte Corporation | $116.00 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589386 |
| Principal investigator 1 | Incyte Corporation | $372.00 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589450 |
| Principal investigator 1 | Incyte Corporation | $31.80 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589544 |
| Principal investigator 1 | Incyte Corporation | $190.80 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589548 |
| Principal investigator 1 | Incyte Corporation | $180.20 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589552 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589561 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589565 |
| Principal investigator 1 | Incyte Corporation | $24.72 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589569 |
| Principal investigator 1 | Incyte Corporation | $9.72 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589574 |
| Principal investigator 1 | Incyte Corporation | $21.20 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589579 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589583 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589588 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589594 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589598 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589603 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589607 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589612 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589616 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589620 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589624 |
| Principal investigator 1 | Incyte Corporation | $201.40 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589627 |
| Principal investigator 1 | Incyte Corporation | $31.80 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589631 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589635 |
| Principal investigator 1 | Incyte Corporation | $58.30 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589640 |
| Principal investigator 1 | Incyte Corporation | $106.00 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589706 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589720 |
| Principal investigator 1 | Incyte Corporation | $169.60 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589725 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589741 |
| Principal investigator 1 | Incyte Corporation | $1,388.00 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589767 |
| Principal investigator 1 | Incyte Corporation | $1,073.20 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589770 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589811 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 04/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589815 |
| Principal investigator 1 | ABBVIE INC. | $1,897.50 | 04/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202467749 |
| Principal investigator 1 | ABBVIE INC. | $988.08 | 04/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202467753 |
| Principal investigator 1 | ABBVIE INC. | $367.85 | 04/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202467767 |
| Principal investigator 1 | ABBVIE INC. | $1,043.28 | 04/01/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202467973 |
| Principal investigator 1 | ABBVIE INC. | $68.00 | 03/26/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202466177 |
| Principal investigator 1 | ABBVIE INC. | $2,064.15 | 03/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202465728 |
| Principal investigator 1 | ABBVIE INC. | $651.36 | 03/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202465743 |
| Principal investigator 1 | ABBVIE INC. | $1,540.00 | 03/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202465808 |
| Principal investigator 1 | Incyte Corporation | $1,965.60 | 03/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589027 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 03/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589039 |
| Principal investigator 1 | PFIZER INC. | $2,101.44 | 03/22/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228861370 |
| Principal investigator 1 | Janssen Research & Development, LLC | $100.00 | 03/20/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187070 |
| Principal investigator 1 | Janssen Research & Development, LLC | $419.00 | 03/20/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187153 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,850.00 | 03/20/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187329 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,077.62 | 03/17/2025 | Non-covered Recipient Entity Skin Care Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226144912 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $578.00 | 03/17/2025 | Non-covered Recipient Entity Skin Care Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226144944 |
| Principal investigator 1 | Incyte Corporation | $120.00 | 03/14/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589045 |
| Principal investigator 1 | Janssen Research & Development, LLC | $58.00 | 03/14/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187107 |
| Principal investigator 1 | Janssen Research & Development, LLC | $58.00 | 03/14/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187340 |
| Principal investigator 1 | Janssen Research & Development, LLC | $58.00 | 03/14/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187371 |
| Principal investigator 1 | PFIZER INC. | $1,495.73 | 03/14/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228861362 |
| Principal investigator 1 | Incyte Corporation | $1,608.00 | 03/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589144 |
| Principal investigator 1 | Incyte Corporation | $702.10 | 03/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589148 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 03/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589152 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 03/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589157 |
| Principal investigator 1 | Incyte Corporation | $2,237.00 | 03/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589170 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 03/12/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589288 |
| Principal investigator 1 | ABBVIE INC. | $289.31 | 03/11/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202462283 |
| Principal investigator 1 | ABBVIE INC. | $7,556.25 | 03/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202459150 |
| Principal investigator 1 | ABBVIE INC. | $10,544.06 | 03/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202459913 |
| Principal investigator 1 | ABBVIE INC. | $3,287.64 | 03/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202460175 |
| Principal investigator 1 | ABBVIE INC. | $639.15 | 03/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202460186 |
| Principal investigator 1 | ABBVIE INC. | $13,973.66 | 03/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202460193 |
| Principal investigator 1 | ABBVIE INC. | $3,285.00 | 03/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202457217 |
| Principal investigator 1 | ABBVIE INC. | $641.72 | 03/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202457554 |
| Principal investigator 1 | ABBVIE INC. | $92.74 | 03/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202458636 |
| Principal investigator 1 | ABBVIE INC. | $1,835.40 | 03/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202455799 |
| Principal investigator 1 | ABBVIE INC. | $27.82 | 03/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202455816 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 03/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589032 |
| Principal investigator 1 | Incyte Corporation | $1,200.00 | 03/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589035 |
| Principal investigator 1 | Incyte Corporation | $195.00 | 03/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240589042 |
| Principal investigator 1 | Incyte Corporation | $1,498.00 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589161 |
| Principal investigator 1 | Incyte Corporation | $1,198.40 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589165 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589194 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589198 |
| Principal investigator 1 | Incyte Corporation | $98.72 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589202 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589206 |
| Principal investigator 1 | Incyte Corporation | $1.24 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589210 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589223 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589226 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589230 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589233 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589237 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589240 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589245 |
| Principal investigator 1 | Incyte Corporation | $80.90 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589249 |
| Principal investigator 1 | Incyte Corporation | $14.84 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589260 |
| Principal investigator 1 | Incyte Corporation | $21.87 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589268 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589272 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589275 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589293 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 03/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589297 |
| Principal investigator 1 | ABBVIE INC. | $139.10 | 02/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202454435 |
| Principal investigator 1 | ABBVIE INC. | $363.15 | 02/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202454439 |
| Principal investigator 1 | ABBVIE INC. | $32.46 | 02/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202454446 |
| Principal investigator 1 | ABBVIE INC. | $150.23 | 02/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202454449 |
| Principal investigator 1 | ABBVIE INC. | $784.00 | 02/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202454452 |
| Principal investigator 1 | ABBVIE INC. | $306.95 | 02/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202454456 |
| Principal investigator 1 | ABBVIE INC. | $824.00 | 02/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202454677 |
| Principal investigator 1 | ABBVIE INC. | $225.72 | 02/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202454681 |
| Principal investigator 1 | ABBVIE INC. | $5,802.00 | 02/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202454684 |
| Principal investigator 1 | ABBVIE INC. | $268.93 | 02/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202454688 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,600.00 | 02/27/2025 | Non-covered Recipient Entity Skin Care Research, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246434443 |
| Principal investigator 1 | ABBVIE INC. | $175.01 | 02/26/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202454048 |
| Principal investigator 1 | ABBVIE INC. | $122.84 | 02/26/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202454113 |
| Principal investigator 1 | ABBVIE INC. | $59.91 | 02/26/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202454117 |
| Principal investigator 1 | ABBVIE INC. | $1,408.00 | 02/26/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202454121 |
| Principal investigator 1 | ABBVIE INC. | $350.00 | 02/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202453857 |
| Principal investigator 1 | Eli Lilly and Company | $3,984.16 | 02/25/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187889992 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 02/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589048 |
| Principal investigator 1 | Incyte Corporation | $42.00 | 02/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589117 |
| Principal investigator 1 | Incyte Corporation | $158.00 | 02/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589121 |
| Principal investigator 1 | Incyte Corporation | $1,003.32 | 02/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589130 |
| Principal investigator 1 | Incyte Corporation | $4,714.24 | 02/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589133 |
| Principal investigator 1 | Incyte Corporation | $58.00 | 02/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589187 |
| Principal investigator 1 | Incyte Corporation | $294.00 | 02/24/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589283 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,421.00 | 02/24/2025 | Non-covered Recipient Entity Skin Care Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226144932 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,000.00 | 02/24/2025 | Non-covered Recipient Entity Skin Care Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226144948 |
| Principal investigator 1 | ABBVIE INC. | $1,104.60 | 02/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202453069 |
| Principal investigator 1 | ABBVIE INC. | $1,073.60 | 02/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH LLC | M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202453210 |
| Principal investigator 1 | ABBVIE INC. | $395.40 | 02/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202453214 |
| Principal investigator 1 | ABBVIE INC. | $824.00 | 02/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202453251 |
| Principal investigator 1 | ABBVIE INC. | $3,300.00 | 02/20/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202453255 |
| Principal investigator 1 | Incyte Corporation | $1,733.00 | 02/19/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589113 |
| Principal investigator 1 | Incyte Corporation | $2,237.00 | 02/19/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589125 |
| Principal investigator 1 | Incyte Corporation | $706.90 | 02/19/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589140 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 02/19/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589305 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 02/19/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589309 |
| Principal investigator 1 | ABBVIE INC. | $572.70 | 02/18/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202452306 |
| Principal investigator 1 | ABBVIE INC. | $852.84 | 02/18/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202452377 |
| Principal investigator 1 | ABBVIE INC. | $127.87 | 02/18/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202452395 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $55.64 | 02/18/2025 | Non-covered Recipient Entity Skin Care Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226144908 |
| Principal investigator 1 | Janssen Research & Development, LLC | $58.00 | 02/14/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187289 |
| Principal investigator 1 | ABBVIE INC. | $784.00 | 02/13/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202451288 |
| Principal investigator 1 | Incyte Corporation | $1,853.10 | 02/11/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240590269 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,600.00 | 02/10/2025 | Non-covered Recipient Entity Skin Care Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226144989 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $900.00 | 02/10/2025 | Non-covered Recipient Entity Skin Care Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226144991 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 02/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589137 |
| Principal investigator 1 | Incyte Corporation | $66.00 | 02/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589263 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,181.60 | 02/07/2025 | Non-covered Recipient Entity Skin Care Research, LLC | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246434439 |
| Principal investigator 1 | ABBVIE INC. | $8,764.62 | 02/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202448525 |
| Principal investigator 1 | ABBVIE INC. | $18,842.79 | 02/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202448529 |
| Principal investigator 1 | ABBVIE INC. | $11,475.72 | 02/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202449728 |
| Principal investigator 1 | ABBVIE INC. | $5,074.20 | 02/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202449766 |
| Principal investigator 1 | ABBVIE INC. | $4,729.20 | 02/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202449788 |
| Principal investigator 1 | ABBVIE INC. | $1,413.66 | 02/06/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202449795 |
| Principal investigator 1 | ABBVIE INC. | $9,148.00 | 02/05/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202446215 |
| Principal investigator 1 | ABBVIE INC. | $3,400.00 | 02/04/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202443792 |
| Principal investigator 1 | ABBVIE INC. | $483.12 | 02/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202443603 |
| Principal investigator 1 | ABBVIE INC. | $453.60 | 02/03/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202443609 |
| Principal investigator 1 | PFIZER INC. | $1,128.60 | 02/03/2025 | Non-covered Recipient Entity Skin Care Research | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228715227 |
| Principal investigator 1 | ABBVIE INC. | $214.65 | 01/30/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202443154 |
| Principal investigator 1 | ABBVIE INC. | $293.04 | 01/28/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202441595 |
| Principal investigator 1 | ABBVIE INC. | $1,501.92 | 01/28/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202441599 |
| Principal investigator 1 | Incyte Corporation | $1,388.00 | 01/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589082 |
| Principal investigator 1 | Incyte Corporation | $372.00 | 01/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589090 |
| Principal investigator 1 | Incyte Corporation | $1,557.60 | 01/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589094 |
| Principal investigator 1 | Incyte Corporation | $1,498.00 | 01/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589097 |
| Principal investigator 1 | Incyte Corporation | $372.00 | 01/27/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589279 |
| Principal investigator 1 | PFIZER INC. | $1,760.13 | 01/24/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228860577 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,950.00 | 01/24/2025 | Non-covered Recipient Entity Skin Care Research Llc | Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD | No dispute reported | 06/30/2026 | 1226144923 |
| Principal investigator 1 | Incyte Corporation | $1,853.10 | 01/21/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240590249 |
| Principal investigator 1 | Eli Lilly and Company | $10,258.13 | 01/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH LLC | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | No dispute reported | 06/30/2026 | 1187889994 |
| Principal investigator 1 | Incyte Corporation | $159.70 | 01/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589056 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 01/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589060 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 01/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589073 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 01/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589077 |
| Principal investigator 1 | Incyte Corporation | $2,237.00 | 01/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589086 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 01/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589101 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 01/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589104 |
| Principal investigator 1 | Incyte Corporation | $1,577.00 | 01/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589107 |
| Principal investigator 1 | Incyte Corporation | $1,707.00 | 01/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589257 |
| Principal investigator 1 | Incyte Corporation | $1,247.40 | 01/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240590254 |
| Principal investigator 1 | Incyte Corporation | $502.00 | 01/17/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240590263 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,122.00 | 01/16/2025 | Non-covered Recipient Entity Skin Care Research, Llc | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175187057 |
| Principal investigator 1 | Incyte Corporation | $1,388.00 | 01/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589063 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 01/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589067 |
| Principal investigator 1 | Incyte Corporation | $1,061.20 | 01/15/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589218 |
| Principal investigator 1 | PFIZER INC. | $418.50 | 01/15/2025 | Non-covered Recipient Entity Skin Care Research LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228860590 |
| Principal investigator 1 | ABBVIE INC. | $824.00 | 01/14/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202438389 |
| Principal investigator 1 | ABBVIE INC. | $106.88 | 01/13/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202438130 |
| Principal investigator 1 | ABBVIE INC. | $704.00 | 01/13/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202438135 |
| Principal investigator 1 | ABBVIE INC. | $2,800.00 | 01/10/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202437946 |
| Principal investigator 1 | Incyte Corporation | $68.73 | 01/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589053 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 01/08/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589213 |
| Principal investigator 1 | Incyte Corporation | $2,662.20 | 01/07/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | No dispute reported | 06/30/2026 | 1240590259 |
| Principal investigator 1 | ABBVIE INC. | $2,066.85 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202434747 |
| Principal investigator 1 | ABBVIE INC. | $1,376.00 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202434751 |
| Principal investigator 1 | ABBVIE INC. | $553.40 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202434779 |
| Principal investigator 1 | ABBVIE INC. | $1,568.00 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202434906 |
| Principal investigator 1 | ABBVIE INC. | $704.00 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202436065 |
| Principal investigator 1 | ABBVIE INC. | $996.00 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202436069 |
| Principal investigator 1 | ABBVIE INC. | $180.84 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH INC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202436138 |
| Principal investigator 1 | Incyte Corporation | $206.10 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589174 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589177 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589183 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589190 |
| Principal investigator 1 | Incyte Corporation | $2.43 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589253 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 01/02/2025 | Non-covered Recipient Entity SKIN CARE RESEARCH, LLC | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240589301 |